Biogen Inc (BIIB)

295.61
NASDAQ : Health Care
Prev Close 295.61
Day Low/High 0.00 / 0.00
52 Wk Low/High 244.28 / 307.76
Avg Volume 1.51M
Exchange NASDAQ
Shares Outstanding 212.12M
Market Cap 60.02B
EPS 17.00
P/E Ratio 18.57
Div & Yield N.A. (N.A)

Latest News

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Novavax, Medicines Co. and Biogen were among the biotech stock movers in premarket trading on July 25.

S&P 500 Hits All-Time High, Alphabet's Fall Pressures Nasdaq

S&P 500 Hits All-Time High, Alphabet's Fall Pressures Nasdaq

Stocks are mixed.

4 Stocks Warren Buffett Would Love

4 Stocks Warren Buffett Would Love

These disparate names seem to fit quite well with the investment approach of the Oracle of Omaha.

Stock Futures Solidly Higher but Alphabet's Earnings Cause Concern

Stock Futures Solidly Higher but Alphabet's Earnings Cause Concern

Stock futures are higher.

The Dow Binges on Earnings

The Dow Binges on Earnings

Get ready for another heavy earnings slate

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens

U.S. stock futures turn higher on Tuesday following earnings from Alphabet.

Biogen Reports Record Quarterly Revenues Of $3.1 Billion, Raises Full Year Revenue Guidance

Biogen Reports Record Quarterly Revenues Of $3.1 Billion, Raises Full Year Revenue Guidance

Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2017 financial results, including: Total revenues of $3.

Alisha A. Alaimo Appointed SVP Of Biogen's US Therapeutic Operations

Alisha A. Alaimo Appointed SVP Of Biogen's US Therapeutic Operations

Biogen (NASDAQ: BIIB) announced today the appointment of Alisha A.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Here are the activist investor's next potential targets.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Biogen To Present Data At Alzheimer's Association International Conference® 2017 (AAIC®)

Biogen To Present Data At Alzheimer's Association International Conference® 2017 (AAIC®)

Biogen (NASDAQ: BIIB) will present data from its Alzheimer's disease programs at the Alzheimer's Association International Conference® 2017 (AAIC®) in London, July 16 - 20, 2017.

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

Biogen Appoints Amy Chevalier Efantis Vice President Of Government Affairs

Biogen Appoints Amy Chevalier Efantis Vice President Of Government Affairs

Biogen (NASDAQ: BIIB) announced today the appointment of Amy Chevalier Efantis as Vice President of Government Affairs, effective July 17.

New Data Reaffirm Clinically Meaningful Benefit Of SPINRAZA® (nusinersen) In Individuals With Spinal Muscular Atrophy Across Disease Severity

New Data Reaffirm Clinically Meaningful Benefit Of SPINRAZA® (nusinersen) In Individuals With Spinal Muscular Atrophy Across Disease Severity

Biogen (NASDAQ: BIIB) will present robust efficacy and safety data from Phase 2 and 3 SPINRAZA ® (nusinersen) studies at the Cure SMA 2017 Annual SMA Conference in Orlando, Fl, June 29 - July 2, 2017.

Biogen Appoints Catherine Steele Senior Vice President Of Corporate Affairs

Biogen (NASDAQ: BIIB) announced today the appointment of Catherine Steele as Senior Vice President of Corporate Affairs, effective July 17.

Biogen's IMRALDI®, An Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion By Committee For Medicinal Products For Human Use

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for IMRALDI ® (also known as SB5), an adalimumab biosimilar candidate referencing...

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

The S&P 500 and Dow slip on a crude oil slump.

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Stocks are mixed as energy lags, health care leads.

Biogen Ready for a Big Bounce

Biogen Ready for a Big Bounce

The chart shows this stock has bottomed.

Chart of the Week: Biogen

The chart shows this stock has bottomed.

Biogen To Report Second Quarter 2017 Financial Results And Strategic Update On July 25, 2017

Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2017 financial results and a strategic update on Tuesday, July 25, 2017, before the financial markets open.

Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer

Biogen (NASDAQ: BIIB) announced today the appointment of Ginger Gregory, PhD, as Executive Vice President, Chief Human Resources Officer, effective July 17.

Biogen Upgraded at UBS on Alzheimer's Clinical Trial Progress

Biogen Upgraded at UBS on Alzheimer's Clinical Trial Progress

Positive clinical trial results and newly priced-in competition breed some optimism for UBS Analyst Carter Gould.

TheStreet Quant Rating: B (Buy)